$TPST
Tempest Therapeutics, Inc. Stock $tpst

$tpst Overview Financials Valuation SEC Filings Company Website

2015 Q4 Form 10-Q Financial Statement

#000154422715000004 Filed on November 05, 2015

Income Statement

Concept	2015 Q4	2015 Q3	2014 Q4
Revenue	$160.0K	$75.00K	$0.00
YoY Change
Cost Of Revenue	$1.160M	$940.0K
YoY Change
Gross Profit	-$1.000M	-$865.0K
YoY Change
Gross Profit Margin	-625.0%	-1153.33%
Selling, General & Admin	$14.57M	$12.91M	$11.02M
YoY Change	32.21%	82.49%	195.44%
% of Gross Profit
Research & Development	$4.670M	$3.998M	$7.270M
YoY Change	-35.76%	-24.92%	-0.14%
% of Gross Profit
Depreciation & Amortization	$540.0K	$300.0K	$190.0K
YoY Change	184.21%	200.0%	216.67%
% of Gross Profit
Operating Expenses	$19.24M	$17.85M	$18.29M
YoY Change	5.19%	43.94%	66.12%
Operating Profit	-$20.24M	-$17.77M
YoY Change		43.33%
Interest Expense	-$240.0K	-$180.0K	-$690.0K
YoY Change	-65.22%	-67.27%	-7000.0%
% of Operating Profit
Other Income/Expense, Net	-$50.00K	$25.00K	$80.00K
YoY Change	-162.5%	4.17%
Pretax Income	-$20.53M	-$17.92M	-$18.89M
YoY Change	8.68%	38.72%	71.73%
Income Tax	$80.00K	$0.00
% Of Pretax Income
Net Earnings	-$20.60M	-$17.92M	-$18.89M
YoY Change	9.05%	38.68%	71.73%
Net Earnings / Revenue	-12875.0%	-23896.0%
Basic Earnings Per Share
Diluted Earnings Per Share	-$171.70	-$149.30	-$171.70
COMMON SHARES
Basic Shares Outstanding	27.28M shares	27.27M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q4	2015 Q3	2014 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$126.7M	$141.7M	$60.20M
YoY Change	110.47%	96.26%	35.59%
Cash & Equivalents	$43.22M	$50.84M	$6.414M
Short-Term Investments	$83.40M	$90.80M	$53.80M
Other Short-Term Assets	$3.200M	$3.600M	$1.600M
YoY Change	100.0%	157.14%	128.57%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$129.9M	$145.3M	$61.88M
YoY Change	109.87%	97.45%	37.27%
LONG-TERM ASSETS
Property, Plant & Equipment	$8.313M	$6.717M	$3.367M
YoY Change	146.9%	116.68%	282.61%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$0.00	$241.0K	$0.00
YoY Change		-59.83%	-100.0%
Other Assets	$0.00	$0.00	$130.0K
YoY Change	-100.0%	-100.0%	30.0%
Total Long-Term Assets	$8.752M	$7.485M	$3.694M
YoY Change	136.92%	91.92%	49.68%
TOTAL ASSETS
Total Short-Term Assets	$129.9M	$145.3M	$61.88M
Total Long-Term Assets	$8.752M	$7.485M	$3.694M
Total Assets	$138.6M	$152.8M	$65.57M
YoY Change	111.39%	97.17%	37.92%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.352M	$4.156M	$2.520M
YoY Change	33.02%	38.53%	52.36%
Accrued Expenses	$7.891M	$5.700M	$7.654M
YoY Change	3.1%	-1.72%	85.78%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$11.24M	$9.863M	$10.17M
YoY Change	10.51%	12.08%	76.2%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$520.0K	$358.0K	$73.00K
YoY Change	612.33%	258.0%	4.29%
Total Long-Term Liabilities	$520.0K	$358.0K	$73.00K
YoY Change	612.33%	258.0%	4.29%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.24M	$9.863M	$10.17M
Total Long-Term Liabilities	$520.0K	$358.0K	$73.00K
Total Liabilities	$11.76M	$10.22M	$10.25M
YoY Change	14.79%	14.84%	75.34%
SHAREHOLDERS EQUITY
Retained Earnings	-$167.9M	-$147.3M	-$94.70M
YoY Change	77.32%		109.61%
Common Stock	$27.00K	$27.00K	$24.00K
YoY Change	12.5%		33.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$126.9M	$142.6M	$55.33M
YoY Change
Total Liabilities & Shareholders Equity	$138.6M	$152.8M	$65.57M
YoY Change	111.39%	97.17%	37.92%

Cashflow Statement

Concept	2015 Q4	2015 Q3	2014 Q4
OPERATING ACTIVITIES
Net Income	-$20.60M	-$17.92M	-$18.89M
YoY Change	9.05%	38.68%	71.73%
Depreciation, Depletion And Amortization	$540.0K	$300.0K	$190.0K
YoY Change	184.21%	200.0%	216.67%
Cash From Operating Activities	-$11.32M	-$12.52M	-$10.53M
YoY Change	7.5%	46.78%	125.0%
INVESTING ACTIVITIES
Capital Expenditures	$2.910M	$1.170M	$1.330M
YoY Change	118.8%	277.42%	533.33%
Acquisitions
YoY Change
Other Investing Activities	$6.730M	-$5.780M	$5.990M
YoY Change	12.35%	-228.16%	204.06%
Cash From Investing Activities	$3.820M	-$6.950M	$4.650M
YoY Change	-17.85%	-265.48%	164.2%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-120.0K	80.00K	160.0K
YoY Change	-175.0%	-188.89%	-300.0%
NET CHANGE
Cash From Operating Activities	-11.32M	-12.52M	-10.53M
Cash From Investing Activities	3.820M	-6.950M	4.650M
Cash From Financing Activities	-120.0K	80.00K	160.0K
Net Change In Cash	-7.620M	-19.39M	-5.720M
YoY Change	33.22%	338.69%	90.67%
FREE CASH FLOW
Cash From Operating Activities	-$11.32M	-$12.52M	-$10.53M
Capital Expenditures	$2.910M	$1.170M	$1.330M
Free Cash Flow	-$14.23M	-$13.69M	-$11.86M
YoY Change	19.98%	54.86%	142.54%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Document Period End Date DocumentPeriodEndDate	2015-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001544227
CY2015Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	12909000	USD
CY2015Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	27278284	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	OvaScience, Inc.
CY2015Q3	ovas	Allocated Share Based Compensation Expense Reversed AllocatedShareBasedCompensationExpenseReversed	900000	USD
CY2015Q1	ovas	Number Of Shares Issued Upon Full Exercise Of Options Granted To Underwriters NumberOfSharesIssuedUponFullExerciseOfOptionsGrantedToUnderwriters	345000	shares
CY2014Q1	ovas	Number Of Shares Represents Partial Exercise Of Overallotment Option Granted To Underwriters NumberOfSharesRepresentsPartialExerciseOfOverallotmentOptionGrantedToUnderwriters	518630	shares
CY2015Q3	ovas	Numberof Treatments NumberofTreatments	1	treatment
CY2015Q2	ovas	Operating Lease Number OperatingLeaseNumber	2	lease
CY2015Q2	ovas	Operating Lease Number Terminated OperatingLeaseNumberTerminated	1	lease
CY2015Q2	ovas	Operating Leases Improvement Allowance OperatingLeasesImprovementAllowance	1200000	USD
CY2015Q2	ovas	Operating Leases Optional Extension Term OperatingLeasesOptionalExtensionTerm	P5Y
CY2013Q4	ovas	Ownership Control Percentage With Disputes Resolved Through Arbitration OwnershipControlPercentageWithDisputesResolvedThroughArbitration	0.5
CY2015Q3	ovas	Potential Treatments In Development PotentialTreatmentsInDevelopment	2	treatment
	ovas	Proceeds From Issuance Of Common Stock From Share Based Compensation Plan Net Of Tax ProceedsFromIssuanceOfCommonStockFromShareBasedCompensationPlanNetOfTax	0	USD
	ovas	Proceeds From Issuance Of Common Stock From Share Based Compensation Plan Net Of Tax ProceedsFromIssuanceOfCommonStockFromShareBasedCompensationPlanNetOfTax	1445000	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2520000	USD
CY2015Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	4156000	USD
CY2014Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	7654000	USD
CY2015Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	5707000	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1138000	USD
CY2015Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1883000	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-26000	USD
CY2015Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-72000	USD
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	150025000	USD
CY2015Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	289947000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	638000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	792000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3464000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4765000	shares
CY2015Q2	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	25200	sqft
CY2014Q4	us-gaap	Assets Assets	65572000	USD
CY2015Q3	us-gaap	Assets Assets	152807000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	61878000	USD
CY2015Q3	us-gaap	Assets Current AssetsCurrent	145322000	USD
CY2014Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	60231000	USD
CY2015Q3	us-gaap	Available For Sale Securities AvailableForSaleSecurities	141672000	USD
CY2014Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	2000	USD
CY2015Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	14000	USD
CY2014Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	28000	USD
CY2015Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	86000	USD
CY2014Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	60257000	USD
CY2015Q3	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	141744000	USD
CY2014Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	44200000	USD
CY2015Q3	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	54800000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	748000	USD
CY2014Q4	us-gaap	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear	32	investment
CY2015Q3	us-gaap	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear	27	investment
CY2015Q3	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1 AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1	27	investment
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18078000	USD
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12125000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6414000	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	50842000	USD
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2015Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24413666	shares
CY2015Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27276410	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24084637	shares
CY2015Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27276410	shares
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	24000	USD
CY2015Q3	us-gaap	Common Stock Value CommonStockValue	27000	USD
CY2014Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12939000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-30664000	USD
CY2015Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-17900000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-52664000	USD
CY2014Q3	us-gaap	Cost Of Revenue CostOfRevenue	0	USD
	us-gaap	Cost Of Revenue CostOfRevenue	0	USD
CY2015Q3	us-gaap	Cost Of Revenue CostOfRevenue	940000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	1091000	USD
CY2014Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	100000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	262000	USD
CY2015Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	300000	USD
CY2014Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.54
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.38
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.66
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.95
CY2013Q4	us-gaap	Equity Method Investment Aggregate Cost EquityMethodInvestmentAggregateCost	1500000	USD
CY2013Q4	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.5
CY2014Q4	us-gaap	Equity Method Investments EquityMethodInvestments	0	USD
CY2015Q3	us-gaap	Equity Method Investments EquityMethodInvestments	241000	USD
CY2014Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-523000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-915000	USD
CY2015Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-316000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1176000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1893000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-139000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1621000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1449000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	798000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1894000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	109000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	439000	USD
CY2014Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-25000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-109000	USD
CY2015Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	141000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	286000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	10247000	USD
CY2015Q3	us-gaap	Liabilities Liabilities	10221000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	65572000	USD
CY2015Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	152807000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10174000	USD
CY2015Q3	us-gaap	Liabilities Current LiabilitiesCurrent	9863000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-5953000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	44428000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	51554000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	125508000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-37443000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-42113000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20064000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-38967000	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-12923000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-30630000	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-17922000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-52618000	USD
CY2014Q3	us-gaap	Operating Expenses OperatingExpenses	12399000	USD
	us-gaap	Operating Expenses OperatingExpenses	29644000	USD
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	17847000	USD
	us-gaap	Operating Expenses OperatingExpenses	51879000	USD
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-12399000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-29644000	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-17772000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-51759000	USD
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	1000000	USD
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	1000000	USD
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	900000	USD
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	900000	USD
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	900000	USD
CY2015Q3	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	100000	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	130000	USD
CY2015Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	USD
CY2014Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-16000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-34000	USD
CY2015Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	22000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-46000	USD
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	73000	USD
CY2015Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	358000	USD
CY2014Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	24000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	38000	USD
CY2015Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	124100000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	51554000	USD
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	3117000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4505000	USD
CY2015Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8600000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3367000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	124063000	USD
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	16820000	USD
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	41104000	USD
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	6418000	USD
CY2015Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	25000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	31000	USD
	us-gaap	Payments To Acquire Interest In Joint Venture PaymentsToAcquireInterestInJointVenture	1500000	USD
	us-gaap	Payments To Acquire Interest In Joint Venture PaymentsToAcquireInterestInJointVenture	1500000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1469000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2323000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	57603000	USD
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	82072000	USD
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1647000	USD
CY2015Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3541000	USD
CY2014Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	51700000	USD
CY2015Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6717000	USD
CY2014Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5325000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14511000	USD
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3998000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13766000	USD
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	0	USD
CY2015Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	109000	USD
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	197000	USD
CY2015Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	527000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-94698000	USD
CY2015Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-147316000	USD
CY2014Q3	us-gaap	Revenues Revenues	0	USD
	us-gaap	Revenues Revenues	0	USD
CY2015Q3	us-gaap	Revenues Revenues	75000	USD
	us-gaap	Revenues Revenues	120000	USD
CY2015Q2	us-gaap	Security Deposit SecurityDeposit	400000	USD
CY2014Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7074000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	15133000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	37022000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	6035000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	14417000	USD
CY2014Q1	us-gaap	Share Price SharePrice	10.00
CY2015Q1	us-gaap	Share Price SharePrice	50
CY2014Q4	us-gaap	Short Term Investments ShortTermInvestments	53817000	USD
CY2015Q3	us-gaap	Short Term Investments ShortTermInvestments	90830000	USD
CY2014Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	5518630	shares
CY2015Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	2645000	shares
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	55325000	USD
CY2015Q3	us-gaap	Stockholders Equity StockholdersEquity	142586000	USD
	us-gaap	Variable Interest Entity Ownership Percentage VariableInterestEntityOwnershipPercentage	0.5
CY2014Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	23766000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	22192000	shares
CY2015Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	27267000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	27020000	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of estimates</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These condensed consolidated financial statements are presented in conformity with U.S. generally accepted accounting principles, which require management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ from such estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001544227-15-000004-index-headers.html	Edgar Link	pending
0001544227-15-000004-index.html	Edgar Link	pending
0001544227-15-000004.txt	Edgar Link	pending
0001544227-15-000004-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
ovas-20150930.xml	Edgar Link	completed
ovas-20150930.xsd	Edgar Link	pending
ovas-20150930x10q.htm	Edgar Link	pending
ovas-20150930xex311.htm	Edgar Link	pending
ovas-20150930xex312.htm	Edgar Link	pending
ovas-20150930xex321.htm	Edgar Link	pending
ovas-20150930xex322.htm	Edgar Link	pending
ovas-20150930_cal.xml	Edgar Link	unprocessable
ovas-20150930_def.xml	Edgar Link	unprocessable
ovas-20150930_lab.xml	Edgar Link	unprocessable
ovas-20150930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TPST
Tempest Therapeutics, Inc. Stock $tpst

2015 Q4 Form 10-Q Financial Statement

#000154422715000004 Filed on November 05, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TPST Tempest Therapeutics, Inc. Stock $tpst

2015 Q4 Form 10-Q Financial Statement

#000154422715000004 Filed on November 05, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TPST
Tempest Therapeutics, Inc. Stock $tpst